Baole Wang

3.8k total citations
6 papers, 227 citations indexed

About

Baole Wang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Baole Wang has authored 6 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Baole Wang's work include Cancer therapeutics and mechanisms (3 papers), Cell death mechanisms and regulation (1 paper) and CAR-T cell therapy research (1 paper). Baole Wang is often cited by papers focused on Cancer therapeutics and mechanisms (3 papers), Cell death mechanisms and regulation (1 paper) and CAR-T cell therapy research (1 paper). Baole Wang collaborates with scholars based in United States and China. Baole Wang's co-authors include Anatol Oleksijew, Steven W. Elmore, Alex R. Shoemaker, David J. Frost, Michael J. Mitten, Scott Ackler, Joy Bauch, Christin Tse, Saul H. Rosenberg and Stephen W. Fesik and has published in prestigious journals such as Blood, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Baole Wang

6 papers receiving 223 citations

Peers

Baole Wang
Jan Molinský Czechia
Thomas Mehrling United Kingdom
Dejan Radeski Australia
Emma Johnson United Kingdom
Michael P. Randall United States
Juliana M. Benito United States
Ami Sabharwal United Kingdom
Shaun Decordova United Kingdom
John C. Byrd United States
Jiro Minami Japan
Jan Molinský Czechia
Baole Wang
Citations per year, relative to Baole Wang Baole Wang (= 1×) peers Jan Molinský

Countries citing papers authored by Baole Wang

Since Specialization
Citations

This map shows the geographic impact of Baole Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baole Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baole Wang more than expected).

Fields of papers citing papers by Baole Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baole Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baole Wang. The network helps show where Baole Wang may publish in the future.

Co-authorship network of co-authors of Baole Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Baole Wang. A scholar is included among the top collaborators of Baole Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baole Wang. Baole Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Zhang, Fei, et al.. (2020). Simulation comparison of SSE and TDOA methods for UHF direction finding of partial discharge in substation area. Energy Reports. 6. 416–423. 3 indexed citations
2.
Ackler, Scott, Xiao Yu, Michael J. Mitten, et al.. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7(10). 3265–3274. 64 indexed citations
3.
Shoemaker, Alex R., Michael J. Mitten, Jessica Adickes, et al.. (2008). Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models. Clinical Cancer Research. 14(11). 3268–3277. 155 indexed citations
4.
Donawho, Cherrie K., Jonathan A. Hickson, Yichun Wang, et al.. (2007). The RTK inhibitor ABT-869, alone and in combination with paclitaxel and/or zoledronic acid, demonstrates significant reduction in the development of both osteoblastic (LuCap 23.1) and osteolytic (PC3-M-Luciferase) tumors intratibially. Molecular Cancer Therapeutics. 6. 2 indexed citations
5.
Donawho, Cherrie K., Yichun Wang, Gail Bukofzer, et al.. (2007). The RTK inhibitor, ABT-869 alone or in combination with various cytotoxic therapies demonstrate significant tumor growth inhibition in orthotopic hepatocellular carcinoma, renal cell carcinoma and prostate xenografts. Molecular Cancer Therapeutics. 6. 1 indexed citations
6.
Shoemaker, Alex R., Michael J. Mitten, Anatol Oleksijew, et al.. (2006). The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma.. Blood. 108(11). 825–825. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Molinský Breakdown of academic impact, for papers by Thomas Mehrling Breakdown of academic impact, for papers by Dejan Radeski Breakdown of academic impact, for papers by Emma Johnson Breakdown of academic impact, for papers by Michael P. Randall Breakdown of academic impact, for papers by Juliana M. Benito Breakdown of academic impact, for papers by Ami Sabharwal Breakdown of academic impact, for papers by Shaun Decordova Breakdown of academic impact, for papers by John C. Byrd Breakdown of academic impact, for papers by Jiro Minami
Rankless by CCL
2026